Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mirvetuximab soravtansine in platinum-sensitive FRα-positive recurrent ovarian, primary peritoneal, or fallopian tube cancer
ISRCTN12633596Phase 2Completed
- Sponsor
- ImmunoGen
- Start
- Oct 2022
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of mirvetuximab soravtansine in ovarian cancer, primary peritoneal cancer (PPC) and fallopian tube cancer (PFTC), sponsored by ImmunoGen. Primary endpoint: Objective response rate. Started Oct 2022; status: completed.
02
Drugs
mirvetuximab soravtansine
03
Conditions
ovarian cancerprimary peritoneal cancer (PPC)fallopian tube cancer (PFTC)
Beyond the preview
Go deeper on ISRCTN12633596.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN12633596.